APOE E4 GENOTYPE PREDICTS SEVERE COVID-19 IN THE UK BIOBANK COMMUNITY COHORT

Chia-Ling Kuo, PhD[1], Luke C Pilling, PhD[1,2], Janice L Atkins, PhD[2], Jane AH Masoli, MBChB [2,3], João Delgado, PhD[2], George A Kuchel MD[1], David Melzer MBBCh PhD[1,2]

[1]Center on Aging, University of Connecticut Farmington, CT, USA

[2]Epidemiology and Public Health Group, University of Exeter Medical School, Exeter, UK

[3]Department of Healthcare for Older People, Royal Devon and Exeter Hospital, Barrack Road, Exeter, UK.

Corresponding author: Professor David Melzer. Epidemiology and Public Health Group, University of Exeter Medical School, College House, St. Luke's Campus, Exeter, EX1 2LU, UK. Email: D.Melzer@exeter.ac.uk

The novel respiratory disease COVID-19 produces varying symptoms, with fever, cough, and shortness of breath being common. In older adults, we found that pre-existing dementia is a major risk factor (OR = 3.07, 95% CI: 1.71 to 5.50) for COVID-19 hospitalization in the UK Biobank (UKB)[1]. In another UK study of 16,749 patients hospitalized for COVID-19 [2], dementia was among the common comorbidities and was associated with higher mortality. Additionally, impaired consciousness, including delirium, is common in severe cases [3]. The *ApoE* e4 genotype is associated with both dementia and delirium [4], with the e4e4 (homozygous) genotype associated with high risk of dementia. We therefore aimed to test associations between *ApoE* e4 alleles and COVID-19 severity, using the UKB data.

UKB is a community cohort currently aged 48 to 86 [5]. COVID-19 laboratory test results for UKB participants in England are available from March 16 to April 26, 2020, the peak period of COVID-19 incidence in the current outbreak [6]. Because testing for older adults during the above period was essentially restricted to hospital in-patients with clinical signs of infection, test positivity is a marker of severe COVID-19 [7].

We analyzed UKB data from genetically European ancestry participants [8] (n=451,367, 90% of sample) attending baseline assessment centers in England (n=398,073), excluding participants who died before the epidemic (n=15,885). Single nucleotide polymorphism (SNP) data for rs429358 and rs7412 was used to determine *ApoE* genotypes: *ApoE* e4e4 homozygotes (n= 9,022, 3%), e3e4 (n= 90,469, 28%), and e3e3 (most common genotype, n= 223,457, 69%) genotype groups (final n=322,948). Mean age was 68 years (SD= 8) with 176,951 females (55%). There were 622 positive COVID-19 patients (Table 1) including 37 e4e4 (positivity rate: 410/100,000) and 401 with e3e3 (179 per 100,000).

A logistic regression model was used to compare e3e4 or e4e4 genotypes to e3e3 for COVID-19 positivity status, adjusted for: sex; age at the COVID-19 test or age on 26th April,

2020 (the last test date); baseline UKB assessment center in England; genotyping array type; and the top five genetic principal components (accounting for possible population admixture).

ApoE e4e4 homozygotes were more likely to be COVID-19 test positives (Odds Ratio = 2.31, 95% Confidence Interval: 1.65 to 3.24, p= 1.19×10^{-6}) compared to e3e3 homozygotes (Table 1). The association was similar after removing participants with *ApoE* e4 associated diseases that were also linked to COVID-19 severity: participants without dementia (OR= 2.39, 95% CI: 1.71 to 3.35); hypertension (OR= 2.41, 95% CI: 1.56 to 3.74); coronary artery disease (myocardial infarction or angina) (OR= 2.43, 95% CI: 1.69 to 3.50) or type 2 diabetes (OR= 2.51, 95% CI: 1.77 to 3.55) (Table 1), based on pre-existing diagnoses from baseline self-reports or hospital discharge statistics (updated to March 2017). The estimates were little changed using 136,146 participants with additional general practice data (up to 2017): participants without dementia (OR= 2.53, 95% CI: 1.46 to 4.39); hypertension (OR= 2.67, 95% CI: 1.34 to 5.32); coronary artery disease (OR= 2.86, 95% CI: 1.65 to 4.98) or type 2 diabetes (OR= 2.73, 95% CI: 1.57 to 4.76). The results were also similar after excluding 51,430 participants related to the 3rd-degree or closer (OR= 2.34, 95% CI: 1.62 to 3.38).

As *ApoE* e4e4 prevalence is higher in people of African descent, we analyzed data for UKB self-reported Black participants: e4e4 was present in 5.2% of Blacks versus 2.3% of Whites. Blacks were more likely to get severe COVID-19 than Whites (e4e4 OR= 3.96, 95% CI: 2.92 to 5.35), which reduced to 3.80 (95% CI: 2.81 to 5.15) after *ApoE* adjustment (e4e4 p = 6.34×10^{-6}), additional to sex, age at test, genotyping array type, and assessment center.

In conclusion, *ApoE* e4 allele increases risks of being hospitalized with COVID-19, independent of pre-existing dementia, cardiovascular disease, and type-2 diabetes. *ApoE* not only affects lipoprotein function (and subsequent cardio-metabolic diseases) but also moderates macrophage pro-/anti-inflammatory phenotypes [9]. The novel coronavirus SARS-

CoV-2 causing COVID-19 uses the ACE2 receptor for cell entry. ACE2 is highly expressed in type II alveolar cells in the lungs, where *ApoE* is one of highly co-expressed genes [10]. *ApoE* e4 allele frequency is higher in people of African ancestry than in Europeans, and preliminary results suggest that *ApoE* e4 prevalence makes a modest contribution to the excess incidence of COVID-19 in Blacks. Further investigation is needed to understand biological mechanisms linking *ApoE* genotypes to COVID-19 severity.

Table 1 Risk of COVID-19 severity comparing participants with e3e4 or e4e4 genotypes to participants with e3e3 genotypes in UK Biobank

	n	Negative or not tested	Positive	Positivity rate per 100,000	OR (95% CI)*	P-value
All						
e3e3	223,457	223,056	401	179	-	-
e3e4	90,469	90,285	184	203	1.14 (0.95, 1.35)	0.15
e4e4	9,022	8,985	37	410	2.31 (1.65, 3.24)	1.19E-06
Excluding dementia						
e3e3	222,968	222,574	394	177	-	-
e3e4	90,013	89,840	173	192	1.09 (0.91, 1.31)	0.338
e4e4	8,877	8,840	37	417	2.39 (1.71, 3.35)	4.26E-07
Excluding hypertension						
e3e3	151,018	150,792	226	150	-	-
e3e4	61,249	61,157	92	150	1.00 (0.79, 1.28)	0.981
e4e4	6,120	6,098	22	359	2.41 (1.56, 3.74)	8.21E-05
Excluding coronary artery disease						
e3e3	204,017	203,684	333	163	-	-
e3e4	82,099	81,948	151	184	1.13 (0.93, 1.37)	2.070E-01
e4e4	8,164	8,132	32	392	2.43 (1.69, 3.50)	1.65E-06
Excluding Type II diabetes						
e3e3	211,482	211,136	346	164	-	-
e3e4	85,983	85,827	156	181	1.11 (0.92, 1.34)	0.275
e4e4	8,616	8,581	35	406	2.51 (1.77, 3.55)	2.42E-07

* adjusted for sex, age at the COVID-19 test or age on 26th April, 2020 (the last test date), assessment center in England, genotyping array type, and the top five genetic principal components

References

1. Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo C-L, Kuchel GA, Melzer D. Pre-existing comorbidities predicting severe COVID-19 in older adults in the UK Biobank community cohort. Submiss. 2020; .

2. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv [Internet]. 2020; : 2020.04.23.20076042. Available from: http://medrxiv.org/content/early/2020/04/28/2020.04.23.20076042.abstract

3. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Hu Y, Li Y, Jin H, Hu B. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: A Retrospective Case Series Study. JAMA Neurol. 2020; .

4. Kuo C-L, Pilling LC, Atkins JL, Kuchel GA, Melzer D. ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants. medRxiv [Internet]. 2020; : 2020.02.12.20022459. Available from: http://medrxiv.org/content/early/2020/02/13/2020.02.12.20022459.abstract

5. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018; 562: 203–9.

6. GOV.UK. Coronavirus (COVID-19) in the UK.

7. GOV.UK. Coronavirus (COVID-19): Using data to track the virus.

8. Pilling LC, Tamosauskaite J, Jones G, Wood AR, Jones L, Kuo CL, Kuchel GA, Ferrucci L, Melzer D. Common conditions associated with hereditary haemochromatosis genetic variants: Cohort study in UK Biobank. BMJ. 2019; 364.

9. Tudorache IF, Trusca VG, Gafencu AV. Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features. Computational and Structural Biotechnology Journal. 2017. p. 359–65.

10. Zhao Y, Zhao Z, Wang Y, Zhou Y, Ma Y, Zuo W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv [Internet].

2020; : 2020.01.26.919985. Available from:

http://biorxiv.org/content/early/2020/01/26/2020.01.26.919985.abstract